BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36344941)

  • 21. A dedicated high-quality service for the management of patients with an inherited risk of colorectal cancer.
    Adams LK; Qiu S; Hunt AK; Monahan KJ
    Colorectal Dis; 2019 Aug; 21(8):879-885. PubMed ID: 30903731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of DNA mismatch repair deficient crypts in random colonoscopic biopsies identifies Lynch syndrome patients.
    Brand RE; Dudley B; Karloski E; Das R; Fuhrer K; Pai RK; Pai RK
    Fam Cancer; 2020 Apr; 19(2):169-175. PubMed ID: 31997046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Faecal Immunochemical Test (FIT) Sensitivity; A Five Year Audit.
    Cole E; Narayanan D; Tiam RN; Shepherd J; Hajjawi MOR
    Br J Biomed Sci; 2024; 81():12862. PubMed ID: 38868754
    [No Abstract]   [Full Text] [Related]  

  • 24. Service evaluation of faecal immunochemical testing and anaemia for risk stratification in the 2-week-wait pathway for colorectal cancer.
    Chapman C; Bunce J; Oliver S; Ng O; Tangri A; Rogers R; Logan RF; Humes DJ; Banerjea A
    BJS Open; 2019 Jun; 3(3):395-402. PubMed ID: 31183456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Faecal immunochemical testing in bowel cancer screening: Estimating outcomes for different diagnostic policies.
    Li SJ; Sharples LD; Benton SC; Blyuss O; Mathews C; Sasieni P; Duffy SW
    J Med Screen; 2021 Sep; 28(3):277-285. PubMed ID: 33342370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The predicted impact and cost-effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndrome.
    Kang YJ; Killen J; Caruana M; Simms K; Taylor N; Frayling IM; Snowsill T; Huxley N; Coupe VM; Hughes S; Freeman V; Boussioutas A; Trainer AH; Ward RL; Mitchell G; Macrae FA; Canfell K
    Med J Aust; 2020 Feb; 212(2):72-81. PubMed ID: 31595523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Faecal immunochemical tests (FIT) versus colonoscopy for surveillance after screening and polypectomy: a diagnostic accuracy and cost-effectiveness study.
    Cross AJ; Wooldrage K; Robbins EC; Kralj-Hans I; MacRae E; Piggott C; Stenson I; Prendergast A; Patel B; Pack K; Howe R; Swart N; Snowball J; Duffy SW; Morris S; von Wagner C; Halloran SP; Atkin WS
    Gut; 2019 Sep; 68(9):1642-1652. PubMed ID: 30538097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient attitudes towards faecal immunochemical testing for haemoglobin as an alternative to colonoscopic surveillance of groups at increased risk of colorectal cancer.
    Bowyer HL; Vart G; Kralj-Hans I; Atkin W; Halloran SP; Seaman H; Wardle J; Wagner Cv
    J Med Screen; 2013; 20(3):149-56. PubMed ID: 24045920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Once-only colonoscopy or two rounds of faecal immunochemical testing 2 years apart for colorectal cancer screening (SCREESCO): preliminary report of a randomised controlled trial.
    Forsberg A; Westerberg M; Metcalfe C; Steele R; Blom J; Engstrand L; Fritzell K; Hellström M; Levin LÅ; Löwbeer C; Pischel A; Strömberg U; Törnberg S; Wengström Y; Ekbom A; Holmberg L; Hultcrantz R;
    Lancet Gastroenterol Hepatol; 2022 Jun; 7(6):513-521. PubMed ID: 35298893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of faecal haemoglobin based triage of bowel symptoms presenting to primary care on colorectal cancer diagnosis.
    Delson D; Ward M; Haddock R; Nobes J; Digby J; Strachan JA; Mowat C
    Colorectal Dis; 2023 Apr; 25(4):787-793. PubMed ID: 36495081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adding family history to faecal immunochemical testing increases the detection of advanced neoplasia in a colorectal cancer screening programme.
    Kallenberg FG; Vleugels JL; de Wijkerslooth TR; Stegeman I; Stoop EM; van Leerdam ME; Kuipers EJ; Bossuyt PM; Dekker E
    Aliment Pharmacol Ther; 2016 Jul; 44(1):88-96. PubMed ID: 27170502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The diagnostic accuracy of the faecal immunochemical test for colorectal cancer in risk-stratified symptomatic patients.
    D'Souza N; Hicks G; Benton SC; Abulafi M
    Ann R Coll Surg Engl; 2020 Mar; 102(3):174-179. PubMed ID: 31697171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Yield of colorectal cancer at colonoscopy according to faecal haemoglobin concentration in symptomatic patients referred from primary care.
    McSorley ST; Digby J; Clyde D; Cruickshank N; Burton P; Barker L; Strachan JA; Fraser CG; Smith K; Mowat C; Winter J; Steele RJC
    Colorectal Dis; 2021 Jul; 23(7):1615-1621. PubMed ID: 33064898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of personalised risk information compared to a positive/negative result on informed choice and intention to undergo colonoscopy following colorectal Cancer screening in Scotland (PERICCS) - a randomised controlled trial: study protocol.
    Steele RJC; Digby J; Chambers JA; O'Carroll RE
    BMC Public Health; 2019 Apr; 19(1):411. PubMed ID: 30991987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single CT colonography versus three rounds of faecal immunochemical test for population-based screening of colorectal cancer (SAVE): a randomised controlled trial.
    Sali L; Ventura L; Mascalchi M; Falchini M; Mallardi B; Carozzi F; Milani S; Zappa M; Grazzini G; Mantellini P
    Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):1016-1023. PubMed ID: 36116454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Colonoscopy screening compliance and outcomes in patients with Lynch syndrome.
    Newton K; Green K; Lalloo F; Evans DG; Hill J
    Colorectal Dis; 2015 Jan; 17(1):38-46. PubMed ID: 25213040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The CRCbiome study: a large prospective cohort study examining the role of lifestyle and the gut microbiome in colorectal cancer screening participants.
    Kværner AS; Birkeland E; Bucher-Johannessen C; Vinberg E; Nordby JI; Kangas H; Bemanian V; Ellonen P; Botteri E; Natvig E; Rognes T; Hovig E; Lyle R; Ambur OH; de Vos WM; Bultman S; Hjartåker A; Landberg R; Song M; Blix HS; Ursin G; Randel KR; de Lange T; Hoff G; Holme Ø; Berstad P; Rounge TB
    BMC Cancer; 2021 Aug; 21(1):930. PubMed ID: 34407780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Faecal haemoglobin concentration in adenoma, before and after polypectomy, approaches the ideal tumour marker.
    Mowat C; Digby J; Cleary S; Gray L; Datt P; Goudie DR; Steele RJ; Strachan JA; Humphries A; Fraser CG
    Ann Clin Biochem; 2022 Jul; 59(4):272-276. PubMed ID: 35235491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance of two faecal immunochemical tests for the detection of advanced neoplasia at different positivity thresholds: a cross-sectional study of the Dutch national colorectal cancer screening programme.
    de Klerk CM; Wieten E; Lansdorp-Vogelaar I; Bossuyt PM; Spaander MC; Dekker E
    Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):111-118. PubMed ID: 30497962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding colorectal cancer risk for symptomatic patients in primary care: A cohort study utilising faecal immunochemical tests and blood results in England.
    Crooks CJ; Banerjea A; Jones J; Chapman C; Oliver S; West J; Humes DJ
    Aliment Pharmacol Ther; 2023 Aug; 58(4):443-452. PubMed ID: 37421214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.